IMBdx
Financials
Valuation Metrics
IMBdx's Market Cap is ₩361B. At end of 2025 it was ₩1418B. Ranked #1967 of 2,421 in KR market (top 81%), #1238 of 1,640 on KOSDAQ (top 75%), #210 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 36.05B KRW | KR#1,967/2,421 Sec#210/231 |
| Revenue | 5.60B KRW | KR#2,331/2,421 Sec#190/231 |
| Net Income | -7.59B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 27.12B KRW | KR#2,354/2,421 Sec#224/231 |
| Net Assets | 25.16B KRW | KR#2,224/2,421 Sec#204/231 |
| Employees | 58 | KR#1,984/2,421 Sec#175/231 |
| Value | ||
| P/B | 1.43x | KR#1,742/2,421 Sec#122/231 |
| P/S | 6.44x | KR#2,200/2,421 Sec#148/231 |
| FCF Yield | -19.50% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -30.16% | KR#2,182/2,421 Sec#175/231 |
| ROA | -27.98% | KR#2,304/2,421 Sec#196/231 |
| Op. Margin | -153.75% | KR#2,325/2,421 Sec#182/231 |
| Revenue Growth | 46.12% | KR#233/2,421 Sec#31/231 |
| Financial Health | ||
| Debt Ratio | 7.77% | KR#86/2,421 Sec#18/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -7.03B KRW | KR#1,593/2,421 Sec#131/231 |
| Cash | 2.08B KRW | KR#2,244/2,421 Sec#213/231 |
| Current Ratio | 21.76x | KR#23/2,421 Sec#10/231 |
| Performance | ||
| 1Y Return | -76.93% | KR#2,342/2,421 Sec#223/231 |
| 1M Return | -18.48% | KR#2,289/2,421 Sec#206/231 |
| From 52W High | -80.64% | KR#2,349/2,421 Sec#220/231 |
| 1Y MDD | -79.22% | KR#2,285/2,421 Sec#206/231 |
| Trading | ||
| Volume | 15,631 shares | KR#1,711/2,421 Sec#168/231 |
| Trading Value | 39.6M KRW | KR#1,923/2,421 Sec#193/231 |
| Foreign Own. | 5.92% | KR#740/2,421 Sec#67/231 |
| Per Share | ||
| EPS | -529 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,756 KRW | KR#2,124/2,421 Sec#176/231 |
Company Info
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.